@CardioBusiness
cardiovascularbusiness.com PCI and CABG fail to improve survival odds for patients with stable heart disease While quality-of-life improvements were seen in patients with regular chest pain, an invasive treatment strategy was not associated with a significant improvement in survival compared to patients... 
cardiovascularbusiness.com FDA approves Abbott’s new defibrillation lead for conduction system pacing The UltiSynq defibrillation lead from Abbott gives clinicians a new option for left bundle branch area pacing. The device has also received CE mark approval. 
cardiovascularbusiness.com Boston Scientific inks $455M deal with global investment firm to work on next-gen heart pump The device in question is a microaxial heart pump for the treatment of acute myocardial infarction-related cardiogenic shock. 
cardiovascularbusiness.com AHA Scientific Sessions 2026: Key trends include AI, negative trial results and multidisciplinary... Meeting chair Joanna Chikwe, MD, spoke to Cardiovascular Business about some of her biggest takeaways from the four-day event. 
cardiovascularbusiness.com NCD and the dawn of a new era: What expanded TAVR coverage means for patient care Curtiss Stinis, MD, has been performing TAVR for nearly two decades. He says the new policies from CMS that expand coverage for asymptomatic patients represent a "momentous step forward" for heart... 